Serotonin Induces Excitatory Postsynaptic Potentials in Apical Dendrites of Neocortical Pyramidal Cells
- G. Aghajanian, G. Marek
- BiologyNeuropharmacology
- 1 April 1997
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
- G. Aghajanian, G. Marek
- Biology, PsychologyBrain Research Reviews
- 1 March 2000
Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release
- G. Aghajanian, G. Marek
- BiologyBrain Research
- 17 April 1999
Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
- G. Marek, R. Wright, D. Schoepp, J. Monn, G. Aghajanian
- BiologyJournal of Pharmacology and Experimental…
- 2000
A close coupling between mGlu2/3 and 5-HT(2A) receptors in the prefrontal cortex that may be relevant for novel therapeutic approaches in the treatment of neuropsychiatric syndromes such as depression and schizophrenia is suggested.
Behavioral Evidence for Interactions between a Hallucinogenic Drug and Group II Metabotropic Glutamate Receptors
- J. Gewirtz, G. Marek
- Biology, ChemistryNeuropsychopharmacology
- 1 November 2000
5-HT2A Receptor-Mediated Regulation of Brain-Derived Neurotrophic Factor mRNA in the Hippocampus and the Neocortex
- V. Vaidya, G. Marek, G. Aghajanian, R. Duman
- Biology, PsychologyJournal of Neuroscience
- 15 April 1997
The results of this study raise the possibility that regulation of BDNF expression by hallucinogenic 5-HT2Areceptor agonists leads to adaptations of synaptic strength in the hippocampus and the neocortex that may mediate some of the acute and long-term behavioral effects of these agents.
5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex.
- G. Marek, G. Aghajanian
- BiologyEuropean Journal of Pharmacology
- 19 February 1999
Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders
- G. Marek, L. Carpenter, C. McDougle, L. Price
- Psychology, BiologyNeuropsychopharmacology
- 1 February 2003
Clinical and preclinical observations suggest that the combination of highly selective 5-HT2A antagonists and SSRIs, as well as strategies to combine high-potency 5- HT2A receptor and5-HT transporter blockade in a single compound, offer the potential for therapeutic advances in a number of neuropsychiatric disorders.
The Selective 5-HT2A Receptor Antagonist M100907 Enhances Antidepressant-Like Behavioral Effects of the SSRI Fluoxetine
- G. Marek, R. Martı́n-Ruiz, A. Abo, F. Artigas
- Psychology, BiologyNeuropsychopharmacology
- 1 December 2005
The results will be discussed in the context that the combined blockade of 5-HT2A receptors and serotonin transporters (SERT) may result in greater efficacy in treating neuropsychiatric syndromes than blocking either site alone.
Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?
Clinical studies with mGlu2/3 agonists may be warranted to further explore the validity of the glutamatergic hypothesis of schizophrenia, which has been implicated in psychotic states and possibly in the etiology of schizophrenia.
...
...